Seeing a different Gleason score on your final pathology report can be surprising or worrying. This usually happens because your biopsy sampled only selected areas, while after surgery the pathologist can examine the removed prostate much more extensively.
This is called upgrading or downgrading. It does not mean surgery changed your cancer; the final pathology has simply provided a more complete picture of its grade.
What Is the Gleason Score?
Your Gleason score tells you how aggressive your prostate cancer looks under a microscope. It combines two cancer patterns, such as 3+4 or 4+3.
Both scores add up to 7, but 4+3 is generally associated with less favourable behaviour because Gleason pattern 4 is predominant. Your doctor may also use the Grade Group to make your cancer easier to understand.
What Are Grade Groups?
The ISUP Grade Group system converts Gleason scores into five groups that are easier to interpret clinically. Grade Group 1 is the lowest-grade category in the Grade Group system, while Grade Group 5 represents the highest-grade disease.
Gleason Score and Grade Group
| Grade Group | Typical Gleason Score | General Meaning |
| Grade Group 1 | 3+3=6 | Only Gleason pattern 3 is identified |
| Grade Group 2 | 3+4=7 | Mainly pattern 3 with a smaller component of pattern 4 |
| Grade Group 3 | 4+3=7 | Mainly pattern 4 with a smaller component of pattern 3 |
| Grade Group 4 | 4+4=8, 3+5=8 or 5+3=8 | High-grade prostate cancer |
| Grade Group 5 | 4+5=9, 5+4=9 or 5+5=10 | Highest-grade category |
This is why a change from Gleason 3+4 to 4+3 is clinically important even though both scores add up to seven: the Grade Group changes from 2 to 3.
Why Can Your Biopsy Grade Differ From the Final Grade?
Your biopsy reflects the cancer grade present in the tissue samples that were taken, but those samples represent only part of the prostate. Prostate cancer can be heterogeneous, meaning different areas can contain different Gleason patterns or Grade Groups.
If a higher-grade or lower-grade area is not represented proportionately in the biopsy samples, the Grade Group assigned after prostatectomy can differ when substantially more tissue becomes available for examination.
Why Is the Final Pathology More Detailed?
After surgery, the entire prostate specimen is available to the pathology laboratory and can be extensively sampled and examined. This allows the pathologist to assess the amount and distribution of different Gleason patterns much more comprehensively than is possible from biopsy cores.
The prostatectomy pathology can also show whether there is extraprostatic extension, seminal-vesicle invasion or a positive surgical margin. If lymph nodes were removed during surgery, these are examined separately for cancer involvement.
What Does Gleason Upgrading Mean?
Gleason upgrading means your final pathology shows a higher cancer grade than your biopsy. This can happen because your biopsy only sampled part of your prostate.
For example, your biopsy may show Gleason 3+3, but the final result may show 3+4. This usually means a higher-grade component was already present but was not represented in the biopsy samples.
How Common Is Upgrading?
There is no single upgrading rate because it varies with your original Grade Group, tumour features and biopsy findings. A percentage reported for one group of patients should not automatically be applied to everyone.
Recent evidence is most useful when it matches your starting biopsy grade. For men whose biopsy shows Grade Group 2 (Gleason 3+4), the research below provides a more specific estimate.
Research Insight
A 2026 systematic review and meta-analysis included 48 studies and 63,119 patients whose biopsy showed Gleason 3+4=7, or Grade Group 2, before radical prostatectomy. Around 23.4% were upgraded to Gleason 4+3 or higher on the prostatectomy specimen, while approximately 3.6% were upgraded to Gleason 8 or higher.
The study also found that clinical tumour stage, PI-RADS score, the amount of cancer in the biopsy and the number of positive biopsy cores were associated with upgrading. In this Grade Group 2 population, the review did not find a significant difference in upgrading according to systematic versus MRI-targeted biopsy approach. These figures therefore describe population-level risk and cannot predict what will happen for you individually.
Why Can a Small High-Grade Area Be Missed?
Your biopsy only checks small parts of your prostate, so it can miss a small area of higher-grade cancer. You may therefore be told that your cancer is lower grade than it actually is overall.
After surgery, the removed prostate is examined much more extensively, making it easier to identify areas that may not have been represented in the biopsy.
Does MRI-Targeted Biopsy Reduce Upgrading?
MRI-targeted biopsy can help your doctor sample suspicious areas identified on MRI and has been associated with a lower likelihood of upgrading at prostatectomy in broader study populations.
However, it cannot prevent upgrading completely. Your biopsy still examines only part of your prostate, while surgery allows the whole gland to be checked.
Evidence Note
A 2023 systematic review and meta-analysis found that MRI-targeted and combined targeted-plus-systematic biopsy approaches were less likely to be upgraded at radical prostatectomy than systematic biopsy alone. Across the included evidence, upgrading occurred in about 27% after MRI-targeted approaches compared with about 42% after systematic biopsy.
However, MRI targeting was also associated with more downgrading in some comparisons, particularly when targeted and systematic biopsy results were combined. This reflects an important limitation of biopsy grading: targeting can preferentially identify a small higher-grade area, while examination of the prostatectomy specimen gives a broader assessment of the cancer as a whole.
Why Can MRI-Targeted Biopsy Sometimes Look Worse Than the Final Pathology?
Your MRI-targeted biopsy focuses on the most suspicious area of your prostate. This can sometimes mean it samples a higher-grade part of the cancer than is typical of the whole tumour.
After surgery, the prostatectomy specimen is assessed much more extensively, so the final Grade Group may be lower than the grade found in a targeted biopsy sample. This does not mean your biopsy was wrong; it simply gives you a different view of the cancer.
What Does Gleason Downgrading Mean?
Downgrading means your final prostatectomy result shows a lower Grade Group than your biopsy. For example, your biopsy may show 4+3=7, but the final result may be 3+4=7.
This can happen because your biopsy sampled a higher-grade area that was less prominent in the whole prostate. It does not necessarily mean your original biopsy was wrong.
Why Are Biopsy and Prostatectomy Grading Rules Slightly Different?
Biopsy and prostatectomy specimens are not graded in exactly the same way. Because a biopsy contains only small tissue samples, a minor higher-grade Gleason pattern is generally incorporated into the biopsy Gleason score.
In a radical prostatectomy specimen, a minor higher-grade pattern representing less than 5% of a tumour focus may instead be reported separately rather than used as the secondary pattern in the Gleason score. This difference in grading rules can contribute to a change between your biopsy and final Grade Group.
Does a Changed Gleason Score Mean the Biopsy Was Wrong?
Usually, no. Your biopsy correctly showed the cancer found in the samples taken, but it could not examine your whole prostate.
After surgery, the pathologist can assess the removed prostate much more extensively. Upgrading or downgrading usually means you now have a more complete picture, not that your original biopsy was wrong.
Can Different Areas of the Prostate Have Different Gleason Scores?
Yes. You can have different cancer grades in different areas of your prostate. One area may contain lower-grade cancer, while another has higher-grade patterns.
Your biopsy may sample only one of these areas. After surgery, the prostatectomy specimen allows much more extensive assessment of the different tumour areas, so your final Grade Group can give you a more complete picture.
Does Upgrading Mean Your Cancer Had Spread?
No. An upgraded Gleason score tells you that your cancer looks more aggressive under the microscope, but it does not mean it has spread.
Your cancer’s stage tells your doctor how far it has grown, while the Grade Group describes its aggressiveness. So, even if your cancer is upgraded after surgery, it may still be confined to your prostate.
Does Downgrading Mean You Are Definitely Cured?
No. A lower Grade Group is reassuring, but it does not mean you are definitely cured. Your margins, stage and other pathology findings still matter.
Your PSA is also important after surgery. If it stays undetectable, that is encouraging, but you still need regular follow-up to check that it remains stable.
Can Upgrading Change Your Follow-Up After Surgery?
Yes, a higher final Grade Group may affect how closely you are monitored after surgery. Your specialist will also consider your other pathology findings and postoperative PSA.
- Higher Recurrence Risk: An upgraded Grade Group may suggest that your cancer has a greater chance of returning.
- Pathological Stage: Your specialist will consider whether the cancer was confined to your prostate or had grown beyond it.
- Surgical Margins: Your margin results show whether cancer cells reached the inked surgical surface of the removed tissue.
- PSA Monitoring: Your postoperative PSA helps your specialist decide whether regular monitoring or further assessment may be needed.
Upgrading does not automatically mean you need additional treatment. Your specialist will consider your Grade Group, stage, margins, lymph nodes and PSA together when planning your follow-up.
Could an Upgraded Result Mean You Need More Treatment?
Possibly, but not always. Your doctor will look at your upgraded Grade Group alongside your stage, margins, lymph nodes and PSA.
If your PSA stays undetectable and your other results are favourable, you may only need monitoring. If your PSA remains detectable or starts rising, your higher Grade Group may lead to discussions about further tests or treatment.
Which Result Should You Use After Surgery: Biopsy or Final Pathology?
After surgery, your final pathology generally provides the most comprehensive tissue-based assessment because the removed prostate has been examined much more extensively than the biopsy samples. Your biopsy shows what was known before treatment.
After surgery, your follow-up is based mainly on your final pathology including Grade Group, pathological stage, surgical margins and any lymph-node findings together with your postoperative PSA.
UK Guidance Note
The Royal College of Pathologists recommends reporting both Gleason score and Grade Group in prostate cancer specimens and recognises that biopsy and radical-prostatectomy grading can differ because substantially different amounts of tissue are available and minor high-grade patterns are handled differently in prostatectomy specimens.
After radical treatment, NICE recommends checking PSA no earlier than six weeks, at least every six months for the first two years and then at least once a year. Your final Grade Group is therefore interpreted alongside your pathological stage, surgical margins and postoperative PSA when planning follow-up rather than being used by itself to decide whether further treatment is needed.
What Should You Ask If Your Gleason Score Changes?
Ask your doctor what changed and whether your Grade Group has moved higher or lower. You can also ask about your final stage, margins and lymph nodes.
Most importantly, ask what your postoperative PSA shows and whether the changed Grade Group affects your follow-up or treatment.
Myth vs Fact
| Myth | Fact |
| Surgery can make your prostate cancer change from one Gleason score to another. | Surgery does not change the cancer grade. The prostatectomy specimen provides much more tissue for examination, so the final grade may differ from the biopsy result. |
| If your final Grade Group is higher, the biopsy must have been wrong. | Not necessarily. Biopsy samples only selected areas, and prostate cancer can contain different grades in different regions. |
| MRI-targeted biopsy completely prevents upgrading. | MRI-targeted biopsy can reduce upgrading compared with systematic biopsy, but it does not eliminate grade changes and can be associated with more downgrading in some comparisons. |
| Gleason 3+4 and 4+3 are basically the same because both equal seven. | They are different Grade Groups. Gleason 3+4 is Grade Group 2, while 4+3 is Grade Group 3 because pattern 4 is predominant in the latter. |
| Upgrading means the cancer must have spread outside the prostate. | Grade and stage are different. A tumour can be upgraded microscopically while still being confined to the prostate. |
| Downgrading means you are cured. | A lower final Grade Group is reassuring, but recurrence risk also depends on stage, margins, lymph nodes and postoperative PSA. |
Key Takeaways
- Biopsy and prostatectomy Grade Groups can differ because biopsy samples only selected areas, while the entire prostate specimen is available for much more extensive assessment after surgery.
- Upgrading means the final Grade Group is higher than on biopsy; downgrading means it is lower. Neither means that surgery changed the biology of the cancer.
- Gleason 3+4 and 4+3 are clinically different even though both total seven because they correspond to Grade Groups 2 and 3.
- MRI-targeted biopsy can reduce upgrading compared with systematic biopsy, but upgrading and downgrading can still occur because biopsy samples only part of the prostate.
- Very small high-grade patterns can be handled differently in biopsy and prostatectomy specimens, which can also contribute to a changed final score.
- Your final Grade Group should be interpreted together with pathological stage, surgical margins, lymph-node findings and postoperative PSA when planning follow-up.
Frequently Asked Questions
1. Can your Gleason score change after robotic prostate surgery?
Yes. Your final Gleason score can change because your biopsy only examines small samples of your prostate. After surgery, the pathologist can examine the removed prostate much more extensively and may find a different cancer grade.
2. What does Gleason upgrading mean after prostate surgery?
Gleason upgrading means your final pathology shows a higher cancer grade than your biopsy. This can happen when your biopsy misses a small area of higher-grade cancer that is identified during the much more extensive examination of the prostatectomy specimen.
3. What does Gleason downgrading mean after prostate surgery?
Downgrading means your final prostatectomy result shows a lower Grade Group than your biopsy. This can happen when your biopsy samples an area of higher-grade cancer that is less prominent in the prostate as a whole.
4. Does a changed Gleason score mean your biopsy was wrong?
Usually, no. Your biopsy accurately shows the cancer found in the samples taken, but it cannot examine your entire prostate. Your final pathology provides a more complete picture because the removed prostate can be assessed much more extensively.
5. Why can different areas of your prostate have different Gleason scores?
Different areas of your prostate can contain different cancer grades. Your biopsy may sample one area, while another area may contain a higher or lower grade. More extensive examination of the removed prostate can reveal these differences.
6. Does Gleason upgrading mean your prostate cancer has spread?
No. An upgraded Gleason score means your cancer looks more aggressive under the microscope, but it does not mean it has spread. Your cancer stage tells your doctor how far it has grown, while your Grade Group describes its aggressiveness.
7. Does Gleason downgrading mean you are cured?
No. A lower Grade Group can be reassuring, but it does not automatically mean you are cured. Your margins, stage, other pathology findings and postoperative PSA also help your doctor assess your situation.
8. Can an upgraded Gleason score change your follow-up after surgery?
Yes, it can. A higher final Grade Group may indicate a greater risk of recurrence. However, your doctor will also consider your stage, margins, seminal vesicles, lymph nodes and PSA when deciding on your follow-up.
9. Could a higher Gleason score mean you need more treatment?
Possibly, but not always. Your doctor will consider your Grade Group alongside your stage, margins, lymph nodes and PSA. If your PSA becomes undetectable and your other results are favourable, you may only need regular monitoring.
10. Which Gleason score should you use after robotic prostate surgery?
After surgery, your final pathology usually gives the clearest tissue-based picture because the removed prostate can be assessed much more extensively than the biopsy samples. Your doctor will use your final Grade Group and other pathology findings together with your postoperative PSA when planning follow-up.
Final Thoughts: Understanding Your Gleason Score After Robotic Prostate Surgery
Your Gleason score can change after robotic prostate surgery because final pathology allows much more extensive examination of the removed prostate than is possible from the small tissue samples taken during biopsy. Whether your cancer is upgraded or downgraded, your specialist will consider the final Grade Group alongside your stage, surgical margins, lymph nodes and postoperative PSA to decide what follow-up you need.
If your Gleason score has changed after robotic prostate surgery in London, our team at Prostate Clinic London can help you understand your final pathology, PSA follow-up and whether the new Grade Group may affect your next steps.
References:
- National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Published 9 May 2019; last updated 15 December 2021. Available at: https://www.nice.org.uk/guidance/ng131
- The Royal College of Pathologists (2024) G084 Dataset for histopathology reports for prostatic carcinoma. October 2024. Available at: https://www.rcpath.org/resourceLibrary/g084-dataset-for-histopathology-reports-for-prostatic-carcinoma.html
- Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R. and Humphrey, P.A. (2016) ‘The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system’, The American Journal of Surgical Pathology, 40(2), pp. 244-252. Available at: https://pubmed.ncbi.nlm.nih.gov/26492179/
- van Leenders, G.J.L.H., van der Kwast, T.H., Grignon, D.J. et al. (2020) ‘The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma’, The American Journal of Surgical Pathology, 44(8), pp. e87-e99. Available at: https://pubmed.ncbi.nlm.nih.gov/32459716/
- Goel, S., Shoag, J.E., Gross, M.D., Al Hussein Al Awamlh, B., Robinson, B., Khani, F., Baltich Nelson, B., Margolis, D.J. and Hu, J.C. (2020) ‘Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis’, European Urology Oncology, 3(1), pp. 10-20. Available at: https://pubmed.ncbi.nlm.nih.gov/31492650/
- Weinstein, I.C., Wu, X., Hill, A. et al. (2023) ‘Impact of magnetic resonance imaging targeting on pathologic upgrading and downgrading at prostatectomy: a systematic review and meta-analysis’, European Urology Oncology, 6(4), pp. 355-365. Available at: https://pubmed.ncbi.nlm.nih.gov/37236832/
- Wu, S., Lin, S.X., Feldman, A.S., Wu, C.-L. and Dahl, D.M. (2026) ‘Gleason Score 3 + 4 (Grade Group 2) prostate cancer on biopsy and postoperative pathological upgrading: a systematic review and meta-analysis’, Clinical Genitourinary Cancer, 24(1), article 102461. Available at: https://pubmed.ncbi.nlm.nih.gov/41290452/